TAMs are usually abundant in the tumor microenvironment and are now known to play an essential role in tumor progression. For example, TAMs influence many aspects of tumorigenesis, such as the growth, survival, invasion, and metastasis of tumor cells, tumor angiogenesis, and the suppression of other tumor-infiltrating immune effector cells. The molecular pathways that regulate these tumor-promoting functions of TAMs are currently under intense investigation. Several recent studies about transgenic murine tumor models have shown that the transcription factor NF-B is a key player in tumor progression with distinct roles in regulating the functions of macrophages and tumor cells in malignant tumors. Here, we outline the evidence for classical and noncanonical NF-B signaling pathways driving the tumor-promoting repertoire of TAMs.
Introduction
A causal relationship between chronic inflammation and cancer is now well-established [1] [2] [3] . One of the key observations supporting this paradigm is the marked infiltration of malignant tumors by a wide array of inflammatory cells. Among these, macrophages have emerged as important drivers of tumor growth, angiogenesis, and metastasis [1, 4, 5] . Understanding the phenotype of these cells in tumors and the molecular mechanism(s) regulating their tumor-promoting functions is currently an area of intense investigation. In the following sections, we review the evidence for IKK/NF-B pathways being activated in TAMs and the impact of this on their functions within tumors.
TAMS
TAMs are recruited into tumors as monocytes from the bloodstream by chemotactic factors such as CCL2, VEGF, M-CSF, and CXCL12 (stromal cell-derived factor 1) [1, 6, 7] , released by malignant and stromal cells in tumors. Pioneering work by Mantovani and colleagues [8] showed that enhanced macrophage recruitment into CCL2-overexpressing tumors promoted the growth of chemically induced fibrosarcomas in mice. VEGF is another major chemoattractant for monocytes and macrophages [9, 10] . Significantly more macrophages were reported in poorly vascularized areas of VEGF-positive than VEGF-negative tumors in human breast carcinoma [10] . In a pancreatic cancer model, inhibition of VEGFR2 inhibited the VEGF-dependent macrophage recruitment in orthotopic tumors [11] . Other studies have shown M-CSF to be a chemoattractant for monocytes [12] and demonstrated its importance in regulating TAM recruitment in breast carcinoma [13] . Similarly, the role of CXCL12 in the recruitment of monocytes and TAM into hypoxic areas of tumors has also been reported [14] .
Ablation of macrophages in such experimental murine tumor models as spontaneous polyoma virus middle T oncoprotein-induced mammary carcinoma inhibits tumor angiogenesis and metastasis [13, 15, 16] . For example, using a macrophage-depletion model, Pollard and colleagues [15] showed that macrophages play a crucial part in driving the "angiogenic switch" associated with the malignant transition of spontaneous murine breast carcinoma and metastases to the lungs [13] . The use of other strategies, such as small interfering RNA to knockdown CSF-1 or clodronate liposomes to deplete systemic macrophages in murine tumor models (such as breast carcinoma, colon carcinoma, F9 teratocarcinoma, and human A673 rhabdomyosarcoma), has also shown a marked reduction in tumor growth and/or angiogenesis [17, 18] . Ojalvo et al. [19] recently provided transcriptomal evidence for many of the ascribed functions of TAMs, including angiogenesis, matrix remodeling, and suppression of immune activation. So it is hardly surprising that increased numbers of TAMs have been correlated with increased tumor angiogenesis/lymph node involvement and/or poor prognosis in several forms of cancer [6, 20] .
TAM AS POLARIZED MACROPHAGE POPULATIONS
Plasticity and heterogeneity of function are hallmarks of the mononuclear phagocyte system [21, 22] . Macrophages respond to diverse environmental signals by expressing any one of a wide array of functional phenotypes. Despite this diversity, two distinct macrophage activation states have been recognized: the M1 (or classically activated) macrophages and the M2 (or alternative activated) macrophages [23, 24] .
Exposure to proinflammatory cytokines and microbial products, such as TNF-␣, IL-1␤, LPS, and IFN-␥, polarizes macrophages into the proinflammatory M1 phenotype, which is characterized by release of their own proinflammatory cytokines, iNOS, RNI, and ROI, and up-regulation of their microbicidal/tumoricidal activity. Anti-inflammatory molecules such as glucocorticoid hormones and Th2 cytokines (IL-4, IL-13, and IL-10), as well as apoptotic cells and immune complexes, induce macrophages to an immunosuppressive M2 activation phenotype [23] . Such "M2" macrophages are thought to be involved in dampening inflammation, producing high levels of anti-inflammatory cytokines (such as IL-10 and TGF-␤), products of the ARG pathway (ARG II, ornithine, and polyamines), expressing high levels of phagocytic capacity, and promoting angiogenesis, tissue remodeling, and repair. A characteristic feature of the M2 macrophages is their IL-12 low /IL-10 high phenotype in response to LPS stimulation.
Murine TAMs show many characteristics that suggest them to be an M2-polarized population [25] . For example, TAMs show impaired expression of proinflammatory cytokines (e.g., IL-12 and TNF-␣), RNI, and MHC II, which correlate functionally to reduced cytotoxicity and antigen-presenting capacity [26 -30] . Conversely, they up-regulate anti-inflammatory molecules, such as IL-10, TGF-␤, and proangiogenic mediators. such as VEGF, COX-2-derived PGE2, and matrix metalloproteinase 9 [2, 19, 26] . Murine TAMs also display other hallmark features of M2 activation, such as up-regulated levels of the M2-specific genes, ARG, macrophage galactose type C-type lectin-2, found in inflammatory zone 1, and Ym1 [25, 31] .
However, it should be noted that TAMs from several mouse tumor models, as well as human tumors (breast, ovarian, and renal cell carcinoma, etc.), also show expression of typical M1 cytokines such as TNF-␣, IL-1␤, IL-23p19, IL-6, and CXCL8, depending on tumor type and stage [32] [33] [34] . This suggests that TAMs may respond to local signals within a given tumor microenvironment. Examples of such signals include TNF-␣ and hypoxia [5, 6, 35] .
CENTRAL ROLE FOR NF-B IN MACROPHAGE POLARIZATION
The transcription factor, NF-B, is now known to regulate the expression of many important genes in macrophages.
Activation of these cells in response to M1 stimuli, such as TLR ligands, TNF-␣, and IL-1␤, is regulated primarily by NF-B [23, 36] . In addition, transcription of several tumorpromoting genes, such as VEGF, IL-6, TNF-␣, and COX2, is also regulated, in part, by NF-B, supporting its crucial role in the activation of TAMs [37, 38] .
NF-B is composed of homo-and heterodimers of the Rel family of the transcription factor, namely p65(Rel A), p50 (NFB1), p52 (NF-B2), c-Rel, and RelB. These proteins are characterized by the presence of a Rel homology domain at the N-terminal, which mediates their ability for DNA binding and dimerization. p50 and p52 exist as precursor protein, p105 and p100, which are processed to give rise to the matured protein. In resting cells, NF-B dimers are bound to IB proteins (IB␣, -␤, and -), thereby inhibiting their DNA-binding capacity and retaining them in a latent state (Fig. 1) .
Activation of TLRs, IL-1R, or TNFR leads to the activation of IKK complex (consisting of IKK␣, IKK␤, and NEMO). This triggers the phosphorylation of IKK␤, which in turn, triggers the phosphorylation, ubiquitination, and degradation of the IBs. Degradation of IB releases free NF-B to translocate into the nucleus and bind to the promoters of the inflammatory genes to trigger transcription. This pathway is also described as the "classical" pathway for NF-B activation, wherein the p65/p50 NF-B heterodimer is the primary mediator of NF-B transcriptional activity for proinflammatory genes.
Besides this NF-B pathway, a noncanonical or "alternative" NF-B pathway has also been described (Fig. 1) [39, 40] . This signaling pathway is activated in response to developmental signals through the LT␤R, CD40, or RANK and is known to be involved centrally in such normal processes as lymph node development and osteoclastogenesis. Activation of these surface receptors involves NIK-induced phosphorylation of IKK␣, which in turn, phosphorylates p100, resulting in the proteolysis of the C-terminal ankyrin repeat domain and generation of the p52 NF-B protein. Downstream events involve the formation of RelB/p52 dimers, which triggers the transcription of organogenic chemokines such as CCL19, CCL21, and CXCL13, required for lymphoid organogenesis. Some reports suggest a crosstalk between the classical and alternative NF-B pathway [41] . The exact role of the noncanonical NF-B pathway in TAM polarization in tumors remains poorly understood.
Although NF-B drives the transcription of many proinflammatory genes in macrophages, additional transcription factors are often required for their maximal expression [33, [42] [43] [44] [45] . For example, genes such as IL-12p40, NOS2, and CXCL10 require STAT1/2, IRF1, -3, -5, and -7, and AP-1 for their transcription [42, 43, 46 -48] . M2 stimuli such as IL-4, IL-13, or IL-10 drive transcription in M2 macrophages through the activation of STAT3 and -6 [49, 50] (Fig. 1) . Activation of these STAT members is not only linked to the transcription of M2-specific genes such as ARG1/2, SOCS3, and SHIP [49, 51, 52] but also to the inhibition of NF-B (Fig. 1) [51, 52] . Other proinflammatory (and tumor-pro-moting) genes, such as TNF-␣, IL-6, and IL-23p19, require NF-B and STAT3 for their transcription.
ROLE OF NF-B IN DRIVING THE TUMOR-PROMOTING FUNCTIONS OF MACROPHAGES
Studies in various inflammation-induced murine tumor models have demonstrated the requirement of NF-B activation in macrophages for tumor promotion [38, 51, [53] [54] [55] [56] . During chronic inflammation, NF-B activation in inflammatory macrophages triggers the release of cytokines such as TNF-␣ and IL-6 [55, 57] , which induce prosurvival signals in tumor cells through NF-B or STAT3 activation in these cells. Macrophages also release a range of other tumor-promoting growth factors such as M-CSF1 and VEGF, as well as cytotoxic agents such as RNI/ROI, which support malignant progression and tumor growth (Fig. 2) [1, 38, 58] . This concept is demonstrated by genetic studies in murine HCC and colitis-associated colon cancer as described below [53, 54, 56] .
Inhibition of the NF-B pathway in liver macrophages (Kupffer cells) by genetic deletion of IKK␤ [55] or MyD88 [59] results in marked reduction in tumor onset and load (Fig. 2, left panel) . Alternatively, inhibition of NF-B in hepatocytes by deletion of IKK␤ [55] or NEMO [54] or expression of the IB␣ super-repressor [56] sensitized them to increased cell death, compensatory proliferation, predisposition to malignancy, and increased tumor load (Fig. 2, right panel) . The mechanism for compensatory proliferation can be explained as follows: inhibition of NF-B in hepatocytes causes inhibition of antiapoptotic genes such as Bcl-XL and growth arrest and DNA damage 45␤, thereby triggering increased cell death. Recognition of these dead cells by Kupffer cells induces the release of proinflammatory cytokines, which supports the growth, proliferation, and survival of the malignant hepatocytes [55] .
In dextran sodium sulfate-induced, colitis-associated colorectal tumors, the intestinal endothelial linings are disrupted, resulting in the exposure of lamina propria macrophages to gut commensals (i.e., resident microbial population of the gut). This triggers macrophages to release inflammatory mediators such as COX2-derived PGE2 and IL-6, which support tumorigenesis. Inhibition of NF-B in these cells, by myeloid-specific IKK␤ deletion, resulted in reduced tumor growth, which was attributed to decreased IL-6 production by TAMs (Fig. 2) [53] . Similarly, the importance of MyD88-induced signaling in innate effectors in driving spontaneous as well as chemically induced intestinal tumor models has been reported recently (Fig. 2) [60] . In an ovarian carcinoma model, Hagemann and colleagues [30] have reported that tumor "educated" macrophages deficient for IL-1R or IKK␤ (and thus, NF-B signaling) induced lesser tumor cell invasion in vitro and show an IL-12p40 high /IL-10 low M1 phenotype in vivo, which correlated Recent data suggest that hypoxia (or extremely low oxygen tension), which is an important tumor microenvironmental factor, can induce the activation of NF-B in murine as well as human macrophages [61, 62] . Upon exposure to hypoxia, murine bone marrow-derived macrophages show NF-B-driven expression of the transcription factor, hypoxia-inducible factor-1 ␣, which regulates the expression of genes such as VEGF and COX2 [61] . This may represent yet another example of how NF-B might mediate that expression of protumoral genes in TAMs under hypoxic conditions.
DEFECTIVE NF-B SHAPES AN IMMUNOSUPPRESSIVE PHENOTYPE OF TUMOR MACROPHAGES
Functional plasticity of macrophage functions during tumor progression has been proposed [5, 31, 35, 63] , and macrophages at early stages of tumor initiation show an M1 phenotype, while TAMs in established tumors show an M2-biased phenotype [5, 52] . Characterization of TAMs from different mouse tumor models (e.g., mammary carcinoma, Lewis lung carcinoma, and chemically induced fibrosarcoma) has shown their impaired capacity to express inflammatory cytokines such as IL-12, TNF-␣, IL-6, and CCL3 but elevated expression of the anti-inflammatory cytokine, IL-10 [26, 27, 52, 64] . The IL-12 low /IL-10 high phenotype, coupled with reduced RNI expression and tumoricidal capacity, confirms the M2 phenotype of these macrophages [52] . Transcriptomal analysis of TAMs from established, chemically induced fibrosarcoma showed impaired expression of several NF-B-inducible cytokines (including IL-12p40 and TNF-␣) upon LPS stimulation [26, 64] . Mechanistically, this was related to a defective NF-B activation in these cells, mediated by the inhibitory p50/p50 NF-B homodimers [65] . It is believed that the p50/p50 homodimer (which lacks the transactivation domain) competes with the canonical p65/p50 heterodimers for the B-binding sites on the inflammatory gene promoters (e.g., IL-12p40 and TNFA), thereby blocking p65/p50 promoter-binding and gene transcription. In line with this, it was observed that depletion of p50, using p50Ϫ/Ϫ mice or p50Ϫ/Ϫ bone marrow chimera, skewed the TAMs to an antitumoral M1 phenotype, characterized by increased IL-12p40 and TNF-␣ but decreased IL-10 production upon IFN-␥/LPS treatment ex vivo [65] . Supporting these observations impaired NF-B activation, and reduced levels of several NF-B members (such as p50, p65, and c-Rel) have also been reported recently in TAMs from mammary carcinoma [29] . These cells also showed defective expression of IL-12 and RNI. Interestingly, another study of murine mammary carcinoma demonstrated that reactivating NF-B using the TLR9 ligand, CpG, and an IL-10R-specific antibody redirected M2-like TAMs (and dendritic cells) to an M1-like phenotype with significant antitumor immunity [66, 67] . Based on these observations, it is proposed that the inhibition of NF-B activation in TAMs mediates their immunosuppressive M2 phenotype [65] .
Hagemann et al. [30] reported recently an IL-12 low /IL-10 high M2 phenotype of TAMs in a mouse ovarian carcinoma model. However, targeted deletion or inhibition of IKK␤ in these cells increased their tumoricidal activity and elevated their expression of NOS2 and IL-12, hallmarks of M1 macrophage polarization. These authors propose that the IKK␤/ NF-B activation was necessary to maintain the IL-12 low /IL-10 high phenotype of TAMs. This is in contrast to the observations discussed above (linking inhibited NF-B activation to the M2 phenotype of TAMs) [52] . The reasons for this apparent contradiction could be manifold, including differences in murine tumor models used, their stage of development, whether they were stimulated ex vivo, the panel of genes used to assess their phenotype, and the mode of NF-B inactivation (e.g., targeting of IKK␤ vs. overexpression of p50/p50 homodimers). Indeed, the diversity of TAM phenotypes between different forms and stage of tumor makes it difficult to extrapolate from one study to another [5, 6, 68] . A more elaborate critique about these two studies has been reviewed recently and so, will not be discussed further here [37] .
THE NONCANONICAL NF-B PATHWAY AND THE TUMOR-PROMOTING FUNCTIONS OF TAMS
A number of observations infer a role for the noncanonical (or alternative) NF-B pathway in regulating macrophage functions in tumors (Fig. 3) . First, macrophages express ligands such as RANKL, LT␣, LT␤, and LIGHT, which trigger the noncanonical NF-B pathway [40, 41] . Second, macrophages express most of the receptors for these ligands, LT␤R, CD40, and RANK. Lastly, many of the protumoral genes expressed by TAMs, such as CXCL12 and VEGFC, are target genes of the noncanonical NF-B pathway [41] . Based on these, two scenarios can be visualized: the activation of the noncanonical NF-B pathway in TAMs may regulate their tumor-promoting functions, and/or TAMs may induce the activation of the noncanonical NF-B pathway in tumor cells to support tumor progression. Examples of both of these situations are presented below.
A few recent studies have implicated components of the noncanonical NF-B pathway in driving chronic, inflammationinduced cancer in transgenic mice models. Tumors that develop in the TRAMP model closely resemble human prostate carcinomas. In this mouse model, prostate cancer occurs as a consequence of the prostate-specific expression of SV40 T antigen. Crossing TRAMP mice with IKK␣ AA/AA mutant mice, which cannot activate IKK␣ [69] , slowed down prostrate tumor progression and metastasis [70] . In this model, the authors propose that tumor-infiltrating inflammatory cells (such as TAMs) activate IKK␣ in the prostate cancer cells (via a noncanonical NF-B pathway), resulting in the repression of the tumor-suppressor gene, Maspin [70] . Blockade of Maspin expression in the prostate cancer cells was seen to correlate directly with their metastatic activity in vivo. In late-stage murine and human prostate cancer, the level of nuclear IKK␣ in tumor cells correlated with metastatic progression, reduced Maspin expression, and infiltration of RANKL-expressing macrophages in the tumors. The RANKL-mediated mechanism of regulating metastasis was also proposed for breast carcinoma and melanoma [70 -72] .
In hepatitis-induced HCC, elevated expression of several noncanonical, NF-B-activating ligands such as LT␣, LT␤, and LIGHT by CD45-enriched liver cells was demonstrated in human and mice tumors [73] . Inhibition of LT␤R, using LT␣␤-transgenic mice, showed suppression of HCC formation. Using in vivo LT␤R stimulation, it was demonstrated that sustained LT␤R signaling in hepatocytes was essential for driving hepatitis-induced HCC. In this scenario, macrophages or Kupffer cells were also shown to be an important source of LT␣, LT␤, and LIGHT.
Interestingly, human pancreatic tumors are usually heavily infiltrated by TAMs, and this has been shown to correlate with poor prognosis, as well as increased lymphangiogenesis and lymphatic metastasis [74] . Constitutive activation of the noncanonical NF-B pathway has been observed in pancreatic tumor cells [75] . Activation of the noncanonical NF-B pathway in tumor cells promotes resistance to apoptosis and their survival. However, it remains to be seen whether TAMs are responsible for triggering the noncanonical NF-B pathway in pancreatic tumor cells, through the release of cytokines such as RANKL, LT␣, or LT␤. Recently, activation of the noncanonical NF-B pathway in the presence of chronic levels of TNF-␣ has been shown to cause super-induction of inflammatory genes such as CCL2 and TNFA [76] and been proposed as one of the mechanisms for inflammation-induced cancer [76] . Further, IKK␣, a key component of this pathway, has been shown to be a negative regulator of the macrophage-inflammatory response [69] . Thus, activation of IKK␣ in TAMs may lead to the negative 
PLASTICITY OF NF-B FUNCTION IN TAMS
A unifying theme emerging from the studies mentioned above is that NF-B regulates the tumor-promoting role of TAMs. However, the multiplicity of NF-B members, their combinatorial interactions, and the distinct temporal, as well as gene regulatory properties of these hetero-and homodimers, suggest plasticity in NF-B function. As explained below, the regulation of TAM function by NF-B may be context-dependent. Although elevated levels of p50/p50 homodimers may repress certain NF-B target genes (e.g., IL-12p40 and TNFA) in TAMs [65] , they may also drive the expression of other genes required to maintain the protumoral phenotype of these cells (Fig. 4) . Indeed, p50/p50 homodimers are necessary for the transcription of the proangiogenic gene COX2, which is often elevated in TAMs [77] [78] [79] . Similarly, IL-10, which is also upregulated by TAMs, is known to be regulated in macrophages by p50 NF-B through the TLR4/tumor progression locus-2/ ERK pathway [80] .
NF-B activation can trigger the expression of proinflammatory or anti-inflammatory genes, depending on the context in which it is being activated (Fig. 4) . This is best illustrated in a study using the rat carrageenin pleurisy model. Pleurisy is an established model of acute inflammation, which is induced by injecting -carageenin in the pleural cavity of Wistar rats. This model is useful, as its proinflammatory and resolving phases are clearly distinguishable and can be characterized by a distinct set of cytokines/effector cells (such as neutrophils and macrophages). Using this model, it was demonstrated that NF-B activation in macrophages during the onset of inflammation is associated with the expression of such proinflammatory genes as TNFA, IL-1B, and NOS2, whereas NF-B activation during the resolution phase is associated with the expression of anti-inflammatory genes such as TGF-␤1 [81] . Analogous to this situation, activation of NF-B in TAMs during tumor initiation would drive inflammatory cytokines such as TNF-␣ and IL-1␤, as demonstrated by several studies. In contrast, TAMs from established tumors have functions in common with resolution such as release of anti-inflammatory cytokines IL-10 and TGF-␤, tissue remodeling, and angiogenesis [25, 58] . Under these settings, it is likely that NF-B activation would support an anti-inflammatory, immunosuppressive M2 phenotype [30] (Fig. 4) . The switch in NF-B function is related primarily to the participation of different NF-B homo-and heterodimers. For example, proinflammatory function of NF-B is driven by the p50/p65 heterodimer, and its immunosuppressive function may be mediated by p50/p50 homodimers, as exemplified in endotoxin tolerance, resolution of inflammation, and TAM from murine fibrosarcoma [65, 81, 82] . Indeed, p50/p50 homodimers are known to activate protumoral genes such as COX2 and TGF-␤ [81] . Other components of the NF-B pathway such as the p52/ p65 heterodimer, p100, RelB, and Bcl3 have positive or negative regulator roles in the expression of inflammatory genes in macrophages [83] . However, how these molecules interact to dictate the exact pattern of gene expression in TAMs has yet to be ascertained. Based on the above discussion, it seems that the plasticity in the TAM phenotype seen during tumor progression may be linked intrinsically to a plasticity of NF-B activation in these cells.
CONCLUSION
It is evident that NF-B activation orchestrates various molecular circuits that promote tumorigenesis. Activation of this transcription factor in TAMs regulates their tumor-promoting functions, and plasticity of NF-B function appears to coincide with the plasticity of TAMs during tumor progression. Although NF-B-mediated expression of inflammatory cytokines such as TNF-␣ and IL-6 by TAMs has been found to contribute crucially to tumor cell survival, cell proliferation at tumor onset and the modulation of NF-B activation in TAMs from established tumors drive them to express an immunosuppressive, tumor-promoting phenotype. In some tumor models, inhibition of NF-B has been attributed to the immunosuppressive phenotype of TAMs, whereas in others, activation of NF-B promotes their protumoral functions. Moreover, a role for the noncanonical NF-B pathway in these cells is emerging. Thus, the mechanisms by which NF-B function is modulated in TAMs may be multiple and dependent on the type and stage of tumor growth. Future studies about the temporal regulation of NF-B in macrophages across different stages of tumor growth and the relative contribution of different NF-B members (p65, c-Rel, p50, Bcl3, etc.) in regulating their phenotype will be crucial to the understanding of NF-B function in TAMs.
